CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) — Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that new preclinical data on tazemetostat, Epizyme’s lead product candidate and first-in-class EZH2 inhibitor, along with other epigenetic target identification efforts, will be presented in poster sessions at the American Association for Cancer Research Annual Meeting 2017 taking place in Washington, D.C., April 1-5, 2017.
“2017 continues to be a transformational year for Epizyme as we work to rewrite cancer treatment through novel epigenetic medicines,” said Rob Bazemore, CEO of Epizyme. “We look forward to sharing these new data on tazemetostat and our innovative approach to advancing our preclinical pipeline with the oncology community at AACR.”
“As we evaluate these data, we are particularly encouraged by new research revealing the important role EZH2 plays in the proliferation of multiple myeloma, and preclinical activity of our first-in-class EZH2 inhibitor, tazemetostat, as both monotherapy and combination therapy in in vitro models of multiple myeloma,” said Richard Chesworth, DPhil, senior vice president of research at Epizyme. “These findings reinforce the potential for tazemetostat as a treatment option across multiple B-cell malignancies.”
Multiple myeloma is a cancer arising from terminally differentiated B-cell lymphocyte plasmablasts. Mounting evidence suggests that EZH2 is an important regulator of B-cell differentiation and may play an important role in clinical B-cell malignancies. Consistent with this role, inhibition of EZH2 alone has shown potent anti-proliferative effects in in vitro and in vivo preclinical models of multiple myeloma.
In a new study being presented at AACR, Epizyme evaluated the efficacy of tazemetostat, an EZH2 inhibitor, as monotherapy and in combination with standard of care…